Literature DB >> 8774132

Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas.

E Hatva1, T Böhling, J Jääskeläinen, M G Persico, M Haltia, K Alitalo.   

Abstract

Capillary hemangioblastomas and hemangiopericytomas are highly vascular central nervous system tumors of controversial origin. Of interest in their pathogenesis are mechanisms regulating endothelial cell growth. The endothelial cell mitogen vascular endothelial growth factor (VEGF) stimulates angiogenesis, and together with its two receptor tyrosine kinases VEGFR-1(FLT1) and VEGFR-2(KDR), is up-regulated during the malignant progression of gliomas. We have analyzed the expression of VEGF and its receptors, the related placental growth factor (PlGF) and the endothelial receptors FLT4 and Tie by in situ hybridization in capillary hemangioblastomas and hemangiopericytomas. VEGF mRNA was up-regulated in all of the hemangiopericytomas studied and highly expressed in the stromal cells of hemangioblastomas. In addition, some hemangioblastoma tumor cells expressed high levels of PlGF. Significantly elevated levels of Tie mRNA, Tie protein, VEGFR-1, and VEGFR-2 but not FLT4 mRNAs were observed in the endothelia of both tumor types. In hemangioblastomas, however, the receptors were also highly expressed by a subpopulation of stromal cells. Consistent results were obtained for a human hemangioblastoma cell line in culture. Up-regulation of the endothelial growth factors and receptors may result in autocrine or paracrine stimulation of endothelial cells and their precursors involved in the genesis of these two vascular tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774132      PMCID: PMC1861732     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  74 in total

1.  A unique autophosphorylation site in the platelet-derived growth factor alpha receptor from a heterodimeric receptor complex.

Authors:  E Rupp; A Siegbahn; L Rönnstrand; C Wernstedt; L Claesson-Welsh; C H Heldin
Journal:  Eur J Biochem       Date:  1994-10-01

2.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

Authors:  N Ferrara; W J Henzel
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

3.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.

Authors:  B Berse; L F Brown; L Van de Water; H F Dvorak; D R Senger
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

4.  The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules.

Authors:  H Gitay-Goren; S Soker; I Vlodavsky; G Neufeld
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

5.  Fibrohistiocytic differentiation in capillary hemangioblastoma.

Authors:  Z Nemes
Journal:  Hum Pathol       Date:  1992-07       Impact factor: 3.466

6.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.

Authors:  E R Horak; R Leek; N Klenk; S LeJeune; K Smith; N Stuart; M Greenall; K Stepniewska; A L Harris
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

7.  Central nervous system lesions in von Hippel-Lindau syndrome.

Authors:  H P Neumann; H R Eggert; R Scheremet; M Schumacher; M Mohadjer; A K Wakhloo; B Volk; U Hettmannsperger; P Riegler; P Schollmeyer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

8.  Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.

Authors:  A Takahashi; H Sasaki; S J Kim; K Tobisu; T Kakizoe; T Tsukamoto; Y Kumamoto; T Sugimura; M Terada
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

9.  Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells.

Authors:  H Sato; M Seiki
Journal:  Oncogene       Date:  1993-02       Impact factor: 9.867

10.  The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells.

Authors:  A Kaipainen; J Korhonen; K Pajusola; O Aprelikova; M G Persico; B I Terman; K Alitalo
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  27 in total

1.  Vascular permeability factor expression in cerebellar hemangioblastomas: correlation with tumor-associated cysts.

Authors:  J Vaquero; M Zurita; S Oya; S Coca; C Salas
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries.

Authors:  T Couffinhal; M Kearney; B Witzenbichler; D Chen; T Murohara; D W Losordo; J Symes; J M Isner
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Hemangiopericytoma in pregnancy: a case report.

Authors:  Mangiola Annunziato; Albanese Alessio; Mannino Stefano; Guerriero Massimiliano; Gessi Marco; Anile Carmelo; Maira Giulio
Journal:  J Neurooncol       Date:  2005-07       Impact factor: 4.130

Review 4.  Hemangioblasts representing a functional endothelio-hematopoietic entity in ontogeny, postnatal life, and CML neovasculogenesis.

Authors:  Gregor Prindull
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

5.  Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.

Authors:  Margaret von Mehren; Cathryn Rankin; John R Goldblum; George D Demetri; Vivien Bramwell; Christopher W Ryan; Ernest Borden
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

6.  VHL-deficient vasculogenesis in hemangioblastoma.

Authors:  Sven Gläsker; Jonathan Smith; Mark Raffeld; Jie Li; Edward H Oldfield; Alexander O Vortmeyer
Journal:  Exp Mol Pathol       Date:  2014-01-04       Impact factor: 3.362

Review 7.  Angiogenesis in brain tumors; pathobiological and clinical aspects.

Authors:  P Wesseling; D J Ruiter; P C Burger
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

8.  Evaluating the extent of involvement in haemangiopericytoma using three-phase bone scintigraphy.

Authors:  Varun Singh Dhull; Saurabh Arora; Girish Kumar Parida; Shamim Ahmed Shamim; Madhavi Tripathi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-01       Impact factor: 9.236

9.  Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.

Authors:  Nicolas Penel; Isabelle Ray-Coquard; Christine Bal-Mahieu; Christine Chevreau; Axel Le Cesne; Antoine Italiano; Emmanuelle Bompas; Stéphanie Clisant; Brigitte Baldeyrou; Amélie Lansiaux; Yves-Marie Robin; Jacques-Olivier Bay; Sophie Piperno-Neumann; Jean-Yves Blay; Charles Fournier
Journal:  Target Oncol       Date:  2013-11-12       Impact factor: 4.493

10.  Haemangiopericytoma of the thyroid gland in combination with Hashimoto's disease.

Authors:  T Hansen; A Gaumann; M Ghalibafian; A Höferlin; A Heintz; C J Kirkpatrick
Journal:  Virchows Arch       Date:  2004-07-09       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.